In clinical trials, the PD-1 inhibitor pembrolizumab was effective and safe for CD19 CAR-T therapy in patients with relapsed B-ALL, enhancing the effects and persistence of the CAR-T [72]. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.